Pharmacogenomics Reporter GenomeWeb News Premium Content Existing subscribers login here. New to Pharmacogenomics Reporter? For a trial subscription click here.

Lilly Official Proclaims Company ‘On
Board’ With Personalized Medicine

[December 5, 2007]

By Turna Ray

While critics of personalized medicine complain that it will segment populations and decrease market shares for big pharma’s cash cow drugs, “market segmentation has really been the norm” at Eli Lilly, according to a company official.

Login | Subscribe